SLC5A2 and type 2 diabetes mellitus: Empagliflozin (EMPA), an inhibitor of sodium/glucose cotransporter 2 (SGLT2) in clinical use to treat type II diabetes and as of late also nondiabetic heart failure (HF) (9, 10), was recently shown to modulate cardiac Na+ channels.